Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 9/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | APOL1 | O14791 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624006 | 0.91 | LIPG (0.33) | LIPGMETAP2NTRK1CNR2 | |
| SCHEMBL13624001 | 0.88 | LIPG (0.33) | LIPGNTRK1 | |
| SCHEMBL13624008 | 0.88 | CNR2 (0.38) | LIPGNTRK1CNR2 | |
| SCHEMBL13624000 | 0.88 | LIPG (0.33) | LIPGMETAP2NTRK1CNR2 | |
| SCHEMBL13624002 | 0.88 | GRM2 (0.33) | LIPGNTRK1 | |
| SCHEMBL13624003 | 0.87 | PTGER4 (0.33) | LIPGNTRK1 | |
| SCHEMBL3992850 | 0.85 | GPR52 (0.34) | GPR52LIPGNTRK1GRIN2B | |
| SCHEMBL12378421 | 0.85 | GPR52 (0.39) | GPR52LIPG | |
| SCHEMBL13846194 | 0.84 | LIPG (0.32) | LIPG | |
| SCHEMBL13624005 | 0.82 | GABRA5 (0.32) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | GPR52 4016/4885LIPG 2233/4885METAP2 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.